Screening for Hep C in U.S. prisons is cost-effective, would benefit the general community

November 2015 (Medical News Today)

Article

A computer model suggests that screening for hepatitis C virus (HCV) in U.S. prisons and treating infected persons is highly cost-effective and would reduce ongoing HCV transmission, the incidence of advanced liver diseases, and liver-related deaths both inside prison and in the general community. A prison-based screening and treatment program could reduce overall health costs as much as $760 million over a 30-year period and most of those savings would take place in the general community. The study is published in Annals of Internal Medicine.

Read more.